Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia; Human Psychopharmacology: Clinical and Experimental; Vol. 35, iss. 4

Xehetasun bibliografikoak
Parent link:Human Psychopharmacology: Clinical and Experimental
Vol. 35, iss. 4.— 2020.— [e2737, 8 p.]
Erakunde egilea: Национальный исследовательский Томский политехнический университет Инженерная школа неразрушающего контроля и безопасности Отделение контроля и диагностики
Beste egile batzuk: Fedorenko O. Yu. Olga Yurievna, Paderina D. Z. Diana, Loonen A. J. M. Anton, Pozhidaev I. V. Ivan, Boyko A. S., Kornetova E. G. Elena Georgievna, Bokhan N. A. Nikolay Aleksandrovich, Wilffert B. Bob, Ivanova S. A. Svetlana Aleksandrovna
Gaia:Title screen
Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic?induced HPRL. Methods: We recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the ?2 test. Results: A comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (?2 = 3.70; p = .05; odds ratio [OR] = 1.30 [0.99–1.69]).
Hizkuntza:ingelesa
Argitaratua: 2020
Gaiak:
Sarrera elektronikoa:https://doi.org/10.1002/hup.2737
Formatua: xMaterials Baliabide elektronikoa Liburu kapitulua
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=662600

MARC

LEADER 00000naa0a2200000 4500
001 662600
005 20250409112255.0
035 |a (RuTPU)RU\TPU\network\33755 
035 |a RU\TPU\network\28277 
090 |a 662600 
100 |a 20200908d2020 k||y0rusy50 ba 
101 0 |a eng 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia  |f O. Yu. Fedorenko, D. Z. Paderina, A. J. M. Loonen [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
330 |a Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic?induced HPRL. Methods: We recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the ?2 test. Results: A comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (?2 = 3.70; p = .05; odds ratio [OR] = 1.30 [0.99–1.69]). 
461 |t Human Psychopharmacology: Clinical and Experimental 
463 |t Vol. 35, iss. 4  |v [e2737, 8 p.]  |d 2020 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a ANKK1 
610 1 |a hyperprolactinemia 
610 1 |a polymorphism 
610 1 |a schizophrenia 
610 1 |a полиморфизм 
610 1 |a шизофрения 
701 1 |a Fedorenko  |b O. Yu.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1973-  |g Olga Yurievna  |3 (RuTPU)RU\TPU\pers\33861  |9 17450 
701 1 |a Paderina  |b D. Z.  |g Diana 
701 1 |a Loonen  |b A. J. M.  |g Anton 
701 1 |a Pozhidaev  |b I. V.  |g Ivan 
701 1 |a Boyko  |b A. S. 
701 1 |a Kornetova  |b E. G.  |g Elena Georgievna 
701 1 |a Bokhan  |b N. A.  |g Nikolay Aleksandrovich 
701 1 |a Wilffert  |b B.  |g Bob 
701 1 |a Ivanova  |b S. A.  |c specialist in the field of ecology and life safety  |c Professor of Tomsk Polytechnic University, doctor of medical sciences  |f 1964-  |g Svetlana Aleksandrovna  |3 (RuTPU)RU\TPU\pers\33859  |9 17448 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Инженерная школа неразрушающего контроля и безопасности  |b Отделение контроля и диагностики  |3 (RuTPU)RU\TPU\col\23584  |9 28375 
801 2 |a RU  |b 63413507  |c 20200908  |g RCR 
856 4 |u https://doi.org/10.1002/hup.2737 
942 |c CF